Drug Profile
Contezolid acefosamil - MicuRx Pharmaceuticals
Alternative Names: MRX 4 - MicuRx PharmaceuticalsLatest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator MicuRx Pharmaceuticals
- Class Antibacterials; Oxazolidinones; Skin disorder therapies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic foot
- Phase II Skin and soft tissue infections
- Phase I Gram-positive infections
Most Recent Events
- 11 Oct 2023 Adverse events and pharmacokinetics data from a phase I trial in Gram-positive infections presented at the IDWeek 2023 (IDW-2023)
- 22 Sep 2023 Contezolid acefosamil receives Fast Track designation for Diabetic foot [IV] (Combination therapy, In the elderly, In adults) in USA
- 22 Sep 2023 Contezolid acefosamil receives Fast Track designation for Diabetic foot [PO, Tablet] in USA